ArticleJournal of atherosclerosis and thrombosis2019
Inflammatory Mediators Across the Spectrum of Ankle-Brachial Index.
Article in Journal of atherosclerosis and thrombosis, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 24 citations in OpenAlex.
- Plasma copeptin and markers of arterial disorder in patients with type 2 diabetes, a cross-sectional study.Cardiovascular diabetology · 2024Article
- Evaluation of Plasma Biomarkers for Causal Association With Peripheral Artery Disease.Arteriosclerosis, thrombosis, and vascular biology · 2024Article
- The Diagnostic Value of Soluble Triggering Receptor Expressed on Myeloid Cells for Patients with Acute Stone Pyelonephritis.Diagnostics (Basel, Switzerland) · 2024Article
- Narrative Review of Biological Markers in Chronic Limb-Threatening Ischemia.Biomedicines · 2024Review
- Association between ankle-brachial blood pressure index and erectile dysfunction in US adults: a large population-based cross-sectional study.Frontiers in endocrinology · 2024Article
- Sodium-glucose co-transporter 2 inhibitor use in patients with diabetes mellitus undergoing endovascular therapy for symptomatic peripheral artery disease.Cardiovascular diabetology · 2023Article
- Assessment of Serum Neopterin as a Biomarker in Peripheral Artery Disease.Diagnostics (Basel, Switzerland) · 2021Article
- Independent Impact of Peripheral Artery Disease on Percutaneous Coronary Intervention.Journal of the American Heart Association · 2020Observational
- Presentation Pattern of Lower Extremity Endovascular Intervention versus Percutaneous Coronary Intervention.Journal of atherosclerosis and thrombosis · 2020Article
- Ankle-Brachial Index is a Predictor of Future Incident Chronic Kidney Disease in a General Japanese Population.Journal of atherosclerosis and thrombosis · 2019Article
- Plasma Copeptin and Risk of Lower-Extremity Amputation in Type 1 and Type 2 Diabetes.Diabetes care · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimPeripheral artery disease (PAD) is a manifestation of atherosclerosis with poor prognosis. It is generally complicated by vascular calcification, which is located either in the intima as patchy infiltrates; or circumferentially in the media, also known as medial arterial calcification (MAC). Obstructive PAD is reflected by low anklebrachial index (ABI ≤ 0.9), whereas MAC is revealed by high ABI (ABI ＞1.4). Considering the increase in cardiovascular mortality at both ends of the ABI spectrum, this study aimed to explore the underlying pathology through cytokines with established prognostic significance; namely pentraxin-3(PTX3), high sensitivity C-reactive protein (hsCRP), copeptin, soluble triggering receptor expressed on myeloid cells-1 (sTREM-1), NT-proBNP, and neopterin.
methodsWe categorized 180 patients with previous multivessel coronary artery bypass grafting surgery into three groups based on their ABI measurements; 60 patients with ABI ≤ 0.9, 60 patients with ABI within 0.91 and 1.4 (normal ABI), and 60 patients with ABI ＞1.4 constituted the "PAD," "normal," "MAC" groups, respectively. The circulating levels of the biochemical markers were determined.
resultsIn the PAD group, the cytokine levels with predominantly proatherogenic actions such as PTX3, hsCRP, copeptin, and sTREM-1 were increased and these cytokine levels declined as the ABI increased. In the MAC group, the cytokine concentrations with pleiotropic actions such as NT-proBNP and neopterin increased and; NT-proBNP and neopterin concentrations decreased as ABI decreased. The linear regression analysis revealed that neopterin (β=0.72), PTX3 (β=－0.32), and copeptin (β=－0.48) were independent predictors of ABI.
conclusionsThese findings suggest that different inflammatory pathways influence the pathology at the opposing ends of the ABI spectrum. Consequently, we suggest that PTX3, copeptin, and neopterin are promising biomarkers for future research.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.